HUTCHMED DRC

Yahoo Finance • 10 days ago

HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2025

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Oct. 02, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated data from several studies of compounds discovered by... Full story

Yahoo Finance • 30 days ago

Save the Date: HUTCHMED to Present R&D Updates on October 31, 2025

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 12, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:HCM; HKEX:13) today announces that it will host a Research & Development update in Shanghai, China, and v... Full story

Yahoo Finance • last month

HUTCHMED Highlights Clinical Data to be Presented at the 2025 World Conference of Lung Cancer and the CSCO Annual Meeting 2025

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 05, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that new and updated data from several studies of compounds discovered by... Full story

Yahoo Finance • 2 months ago

HUTCHMED CEO takes leave of absence; CFO Johnny Cheng appointed acting CEO

HUTCHMED (HCM [https://seekingalpha.com/symbol/HCM]) has announced [https://seekingalpha.com/pr/20209647-hutchmed-announces-appointment-of-acting-chief-executive-officer] that CEO Weiguo Su will take a leave of absence for health reasons.... Full story

Yahoo Finance • 2 months ago

HUTCHMED Announces Appointment of Acting Chief Executive Officer

HONG KONG and SHANGHAI and FLORHAM PARK, N.J, Aug. 25, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that Dr Weiguo Su, an Executive Director of the Company, will take a leave... Full story

Yahoo Finance • 2 months ago

Thailand Construction Equipment Market Report 2025-2030 - Booming Manufacturing Drives Material Handling Equipment Demand in Thailand

Dublin, Aug. 22, 2025 (GLOBE NEWSWIRE) -- The "Thailand Construction Equipment Market Research Report 2025-2030" has been added to ResearchAndMarkets.com's offering. The Thailand Construction Equipment Market was sized at 14,786 unit... Full story

Yahoo Finance • 2 months ago

HUTCHMED Completes Patient Enrollment of SANOVO Phase III Trial of ORPATHYS® and TAGRISSO® Combination as a First-Line Therapy for Certain Lung Cancer Patients in China

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Aug. 20, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces the completion of patient enrollment of SANOVO, a China Phase III study of... Full story

Yahoo Finance • 3 months ago

HUTCHMED to announce 2025 half-year results on August 7

HONG KONG/SHANGHAI/FLORHAM PARK - HUTCHMED (China) Limited (Nasdaq/AIM:HCM; HKEX:13) will release its financial results for the first half of 2025 on Thursday, August 7, 2025, the biopharmaceutical company announced in a press release. Th... Full story

Yahoo Finance • 3 months ago

HUTCHMED appoints Deutsche Bank as joint corporate broker in London

HONG KONG - HUTCHMED (China) Limited (Nasdaq/AIM:HCM; HKEX:13) announced Wednesday it has appointed Deutsche Bank AG (ETR:DBKGn), trading as Deutsche Numis, as its joint corporate broker in London with immediate effect. The appointment... Full story

Yahoo Finance • 3 months ago

China approves ORPATHYS-TAGRISSO combo for lung cancer with MET amplification

HONG KONG - China’s National Medical Products Administration (NMPA) has approved the combination of ORPATHYS (savolitinib) and TAGRISSO (osimertinib) for treating patients with locally advanced or metastatic EGFR mutation-positive non-squa... Full story

Yahoo Finance • 4 months ago

HCM Makes Bullish Cross Above Critical Moving Average

In trading on Monday, shares of HUTCHMED (China) Ltd (Symbol: HCM) crossed above their 200 day moving average of $16.00, changing hands as high as $16.15 per share. HUTCHMED (China) Ltd shares are currently trading up about 4% on the day.... Full story

Yahoo Finance • 5 months ago

International companies to host live webcasts at Deutsche Bank’s Depositary Receipts Virtual Investor Conference on May 15, 2025

Virtual Investor Conferences NEW YORK, May 13, 2025 (GLOBE NEWSWIRE) -- Deutsche Bank today announced the lineup for its Depositary Receipts Virtual Investor Conference (“dbVIC”) on Thursday, May 15, 2025 featuring live webcast presentati... Full story

Yahoo Finance • 7 months ago

HUTCHMED Highlights Savolitinib SAVANNAH Phase II and Other Data at European Lung Cancer Congress 2025

HUTCHMED (China) Limited — SAVANNAH Phase II trial demonstrated high and durable response rates with savolitinib plus TAGRISSO® in MET-high lung cancer, representing a promising chemo-free oral treatment strategy to address mechanisms of... Full story

Yahoo Finance • 7 months ago

HUTCHMED and Innovent Jointly Announce that the FRUSICA-2 Phase II/III Study of Fruquintinib and Sintilimab Combination Has Met its Primary Endpoint in Advanced Renal Cell Carcinoma in China

HUTCHMED (China) Limited HONG KONG and SHANGHAI and FLORHAM PARK, N.J., March 19, 2025 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) and Innovent Biologics, Inc. (“Innovent”) (HKEX: 01801), today jo... Full story

Yahoo Finance • last year

HUTCHMED Announces NDA Acceptance in China for Tazemetostat for the Treatment of Relapsed or Refractory Follicular Lymphoma with Priority Review Status

HUTCHMED (China) Limited HONG KONG and SHANGHAI and FLORHAM PARK, N.J., July 04, 2024 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that the New Drug Application (“NDA”) for tazemeto... Full story

Yahoo Finance • 2 years ago

HUTCHMED Announces Continued Inclusion of ELUNATE® (fruquintinib) and SULANDA® (surufatinib) in the National Reimbursement Drug List in China at Current Terms

HUTCHMED (China) Limited HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM, HKEX:​13) today announces that under the 2023 simple renewal mechanis... Full story

Yahoo Finance • 2 years ago

HUTCHMED Completes Patient Enrollment of a Bridging Study of Tazemetostat in Patients with Relapsed/Refractory Follicular Lymphoma in China

HONG KONG and SHANGHAI and FLORHAM PARK, N.J., Sept. 11, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has completed patient enrollment of a bridging study of tazemetos... Full story

Yahoo Finance • 2 years ago

HUTCHMED Receives Breakthrough Therapy Designation in China for Savolitinib for Gastric Cancer

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., Aug. 28, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that the Center for Drug Evaluation of China’s National Medical Pro... Full story

Yahoo Finance • 2 years ago

HUTCHMED Announces that the Sovleplenib Phase III ESLIM-01 Study Met Its Primary Endpoint in Primary Immune Thrombocytopenia in China

— Randomized, double-blind, controlled trial met primary endpoint of durable response rate and all secondary endpoints — — Overall safety consistent with sovleplenib known profile — — Plans for regulatory submission underway in China, wh... Full story

Yahoo Finance • 2 years ago

HUTCHMED Initiates Phase I Study of its novel SHP2 inhibitor HMPL-415 for Advanced Malignant Solid Tumors in China

HONG KONG and SHANGHAI, China and FLORHAM PARK, N.J., July 09, 2023 (GLOBE NEWSWIRE) -- HUTCHMED (China) Limited (“HUTCHMED”) (Nasdaq/AIM:​HCM; HKEX:​13) today announces that it has initiated a Phase I study in China of HMPL-415, an inve... Full story